Three different University ranking systems have placed Barts and the London School of Medicine and Dentistry in the top 10 institutes in the world and the UK.
The Leiden Ranking 2014, the Guardian University Guide 2015 and the Complete University Guide 2015 have all ranked the medical and dental school (part of Queen Mary University of London) in the top tier, using a variety of measurements, showing that medical research and teaching at Barts and The London School of Medicine and Dentistry is absolutely world-class.
The CWTS Leiden Ranking 2014 measures the scientific performance of 750 major universities worldwide. Using a sophisticated set of bibliometric indicators, the ranking aims to provide highly accurate measurements of the scientific impact of universities and of universities' involvement in scientific collaboration. The CWTS Leiden Ranking 2014 is based on Web of Science indexed publications from the period 2009–2012. The main outcomes of the ranking are summarized in a press release, and Barts and The London's impact ranking by two diffferent metrics are illustrated in the tables below.
PP(top 10%) = Proportion of top 10% publications: Proportion of the publications of a university belonging to the top 10% of their field.
MNCS = Mean Normalised Citation Score: Average number of citations of the publications of a university, normalised for field differences and publication year.
Filtered by Medical Sciences. Publication number (P) lower limit set at 500.
For teaching, the Complete University Guide, which ranks UK universities in nine quality factors important to students, placed Barts and The London Medical School 4th (up from 7th last year) and Denistry 1st (up from 11th last year).
Similarly, The Guardian University Guide 2015 ranked Barts and The London 2nd in London (6th in the UK) for Medicine; for Dentistry, we were ranked 1st in London (2nd in the UK).
Why not join us and become part of one of the best medical and dental schools in the world!
Undergraduate Courses: http://www.smd.qmul.ac.uk/undergraduate/index.html
Postgraduate Courses: http://www.smd.qmul.ac.uk/graduatestudies/index.html
Work for us: http://www.jobs.qmul.ac.uk/
Congratulations to Professor Adrian Newland CBE from the Blizard Institute who has been elected as President of the International Society of Hematology (ISH). He will take up the post for a period of two years from September this year.
Professor Newland comments: “I am honoured to have been elected the next President of the ISH and to continue the work of the Society in developing educational opportunities for developing countries. I will be working with national societies and the three divisions of the Society – the Inter-American, Asian-Pacific and the European-African Divisions – to pursue these aims.”
Professor Newland was previously Chair of the Education and Training Committee and helped develop the Society’s journal 'Hematology', which is now available electronically to ISH members, and of which he is a senior editor. In addition to supporting local meetings of the Society, he will be holding its international meeting in Glasgow in 2016, showcasing developments in haematology and training opportunities.
Queen Mary University of London is delighted to announce a ground-breaking new research partnership with UCL Institute of Neurology (under UCLPartners) and the charity Brain Tumour Research. The partnership begins a new chapter in long-term, sustainable and continuous research into brain tumours, the biggest cancer killer of children and adults under 40.
Formally presented to MPs at a reception in Speaker’s House today, the research is led by Professor Silvia Marino, a leading brain tumour scientist and neuropathologist based within Queen Mary’s Blizard Institute. Sheer, also from Queen Mary, and Professor Brandner and Dr Rees at UCL Institute of Neurology will be the other key partners in this initiative.
The research will focus on glioblastoma multiforme (GBM), the most common and most aggressive type of malignant brain tumour found in humans. The aim of the research is to increase our understanding of the cells within the brain from which GBM originates. The team will look at how this particular type of brain tumour develops from normal cells, and determine which genes and biological functions control its behaviour. By uncovering this essential knowledge, the clinical evaluation of each individual patient can be improved and better and more specific drugs which target the tumour cells can be identified.
Silvia Marino, Professor of Neuropathology at Queen Mary University of London, comments: “We know a cure for glioblastoma can and will be found – and this funding boost will hopefully enable significant steps towards a breakthrough. The plan for our centre of excellence is to specialise in adult glioblastoma as we have a wealth of experience in the field, ranging from preclinical experimental models to advanced genomics for direct patient benefit. We also look forward to strengthening collaborative links between us and the UCL Institute of Neurology.”
The partnership is part of the charity’s aim for a £20 million investment in brain tumour research over the next five years. Brain Tumour Research aims to establish seven Research Centres of Excellence across the UK, building a ‘critical mass’ of research teams and aiming to bring the UK to the forefront of brain tumour research.
With secure long-term funding, researchers will be able to pursue the sustainable and continuous research so desperately needed by the scientists and clinicians working in the heavily underfunded field of brain tumour research. Promising scientists will be trained up through the ranks and as specialist brain tumour expertise and knowledge builds, experienced researchers can then move between Centres to encourage cross-pollination of the very best thinking at the cutting-edge of brain tumour research.
Sue Farrington Smith, Chief Executive of Brain Tumour Research, comments: “Today we will be forming a powerful new network of researchers in order to accelerate progress in brain tumour research and make a clinical difference. All partners involved share a vision of a sustainable and secure environment for research into brain tumours in the UK, ultimately creating better futures for all those diagnosed and living with a brain tumour. We are determined to do all we can to change this, and to one day find a cure for this devastating disease.”
Queen Mary would also like to thank Barts Charity, for their supporting role in this partnership.